PTC Therapeutics, Inc. Accumulated Other Comprehensive Income
PTC Therapeutics, Inc. (PTCT) had Accumulated Other Comprehensive Income of $6.02 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-30
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.02M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $8.47M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $10.50M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $5.93M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $6.02M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $8.47M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $10.50M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $5.93M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $7.36M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$13.95M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | -$25.89M 10-K · filed 2026-02-19 | |
| 2024-09-30 | -$4.34M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$16.50M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$5.56M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | -$1.28M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $9.61M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | -$1.43M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$1.59M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $4.80M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $36.20M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $10.25M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$18.61M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | -$24.28M 10-K · filed 2023-02-21 | |
| 2021-09-30 | -$32.96M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | -$46.09M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | -$38.74M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | -$60.96M 10-K · filed 2022-02-22 | |
| 2020-09-30 | -$35.73M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | -$10.02M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$1.99M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | -$10.58M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $616.00K 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $1.92M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $805.00K 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $1.46M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $1.63M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $1.85M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $4.95M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.97M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $3.01M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $2.00M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$876.00K 10-Q · filed 2017-05-08 | |
| 2016-12-31 | -$1.49M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $756.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $885.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.08M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$1.20M 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$1.13M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$495.00K 10-Q · filed 2015-11-09 | |
| 2015-03-31 | -$736.00K 10-Q · filed 2015-07-31 | |
| 2014-12-31 | -$737.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | -$69.00K 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $90.00K 10-Q · filed 2014-11-06 | |
| 2014-03-31 | $80.00K 10-Q · filed 2014-08-07 | |
| 2013-12-31 | $70.00K 10-K · filed 2016-02-29 | $70.39K 10-K · filed 2014-03-06 |
| 2013-09-30 | -$40.47K 10-Q · filed 2013-11-14 | |
| 2013-06-30 | -$772.00 10-Q · filed 2013-11-14 | |
| 2010-12-31 | $3.61K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |